Xeltis’ pioneering approach to heart valve therapy was the focus of today’s plenary session “Bioresorbable valve therapy: tomorrow’s world” at EuroPCR. Global thought leaders in interventional cardiology discussed the unique science, early data and potential benefits of Endogenous Tissue Restoration (ETR) at the well-attended session.
“This innovative treatment approach has the potential to reduce complications, re-interventions and healthcare costs, while improving quality of life for patients with heart valve disease. This would represent a major leap forward in heart valve therapy,” said Martin B. Leon, M.D., director at the Center for Interventional Vascular Therapy at Columbia University Medical Center and New York-Presbyterian Hospital, one of the speakers at the session.
The first study results from Xeltis’ preclinical aortic valve program were presented today during the same plenary session. The promising data showed good hemodynamic performance and fully functional valves in vivo six months after implantation. Read the full press release here.
View our EuroPCR highlights:
Learn more about our RestoreX technology.
